DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 04:47:50 2024-05-28 am EDT | ||
| 312.8 EUR | -0.15% |
|
| Current month | +0.81% | ||
| 1 month | +1.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 312.8 | -0.15% |
| 24-05-27 | 313.3 | -0.01% |
| 24-05-24 | 313.3 | -0.30% |
| 24-05-23 | 314.2 | +0.30% |
| 24-05-22 | 313.3 | +0.34% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 04:47 am EDT
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8Q |
| ISIN | DE000ME7D8Q0 |
| Date issued | 2024-01-23 |
| Maturity | 2024-12-20 (206 Days) |
| Parity | 1 : 1 |
| Emission price | 302.9 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 314.2 € |
|---|---|
| Lowest since issue | 297.4 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Certificates
- Certificat
